Mirati Therapeutics, Inc. (NASDAQ:MRTX) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

Several other research firms have also recently issued reports on MRTX. HC Wainwright set a $10.00 target price on Mirati Therapeutics and gave the stock a “buy” rating in a research report on Saturday, March 11th. Zacks Investment Research cut Mirati Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 4th. Finally, Jefferies Group LLC reiterated a “hold” rating and set a $4.50 target price on shares of Mirati Therapeutics in a research report on Monday, June 12th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $7.54.

Shares of Mirati Therapeutics (NASDAQ:MRTX) traded up 15.15% on Thursday, reaching $3.80. The company’s stock had a trading volume of 172,676 shares. The company’s market capitalization is $94.77 million. Mirati Therapeutics has a 12-month low of $2.70 and a 12-month high of $7.22. The company’s 50-day moving average is $3.36 and its 200 day moving average is $4.73.

TRADEMARK VIOLATION NOTICE: “Mirati Therapeutics, Inc. (NASDAQ:MRTX) Upgraded by ValuEngine to “Sell”” was first reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/07/08/mirati-therapeutics-inc-nasdaqmrtx-upgraded-by-valuengine-to-sell.html.

Several hedge funds have recently added to or reduced their stakes in the company. Boxer Capital LLC boosted its stake in Mirati Therapeutics by 37.0% in the first quarter. Boxer Capital LLC now owns 1,037,994 shares of the biotechnology company’s stock valued at $5,398,000 after buying an additional 280,059 shares in the last quarter. Aviva Holdings Ltd. boosted its stake in Mirati Therapeutics by 44.6% in the first quarter. Aviva Holdings Ltd. now owns 2,880,702 shares of the biotechnology company’s stock valued at $14,980,000 after buying an additional 888,617 shares in the last quarter. Sabby Management LLC boosted its stake in Mirati Therapeutics by 150.4% in the first quarter. Sabby Management LLC now owns 249,735 shares of the biotechnology company’s stock valued at $1,299,000 after buying an additional 150,000 shares in the last quarter. Omega Advisors Inc. acquired a new stake in Mirati Therapeutics during the first quarter valued at about $520,000. Finally, Broadfin Capital LLC boosted its stake in Mirati Therapeutics by 153.1% in the first quarter. Broadfin Capital LLC now owns 2,090,801 shares of the biotechnology company’s stock valued at $10,872,000 after buying an additional 1,264,800 shares in the last quarter. Hedge funds and other institutional investors own 64.80% of the company’s stock.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.